<DOC>
	<DOCNO>NCT02421120</DOCNO>
	<brief_summary>There establish evidence adult patient Cystic Fibrosis ( CF ) may alter antibiotic pharmacokinetics compare non-CF patient . Ceftolozane/Tazobactam newly approve broad spectrum intravenous antibiotic , potent vitro activity multidrug resistant Pseudomonas aeruginosa , common pathogen implicate CF pulmonary exacerbation . This study determine pharmacokinetics tolerability ceftolozane/tazobactam 20 adult CF patient admit pulmonary exacerbation one 4 participate hospital US . Patients remain standard care IV antibiotic receive 4-6 dos ceftolozane/tazobactam 3 gram every 8 hour . Blood sample final dose determine concentration pharmacokinetics ceftolozane tazobactam . Safety tolerability assess throughout 3 day study .</brief_summary>
	<brief_title>Population Pharmacokinetics Safety Intravenous Ceftolozane/Tazobactam Adult Cystic Fibrosis Patients</brief_title>
	<detailed_description>Participants receive 4-6 dos ceftolozane/tazobactam 3 gram every 8 hour , addition standard intravenous antibiotic therapy select site . Just prior final dose , total six blood sample collect measure ceftolozane tazobactam concentration . Data fit population pharmacokinetic model . The final model utilized Monte Carlo simulation determine probability several different dose regimen retain concentration minimum inhibitory concentration ( MIC ) least 39 % dose interval . These data utilize determine optimize dose regimen adult CF .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<mesh_term>Ceftolozane , tazobactam drug combination</mesh_term>
	<criteria>1 . Age 18 year old 2 . Documented diagnosis CF 3 . Acute pulmonary exacerbation primary reason admission hospital requirement receive systemic antibiotic treatment 4 . If female , subject must nonpregnant nonlactating . Females either childbearing potential childbearing potential , acceptable mode birth control abstinence sexual intercourse , oral/parenteral contraceptive , barrier method 1 . History moderate severe hypersensitivity allergic reaction Î²lactam antibiotic ( history mild rash cephalosporin follow uneventful reexposure contraindication ) 2 . Prior ( within 24 hour first dose study drug ) concomitant receipt piperacillin/tazobactam probenecid 3 . History lung transplant 4 . Moderate severe renal dysfunction define creatinine clearance &lt; 50 mL/min ( calculate CockcroftGault equation use actual body weight ) requirement continuous renal replacement therapy hemodialysis 5 . A hemoglobin less 8 gm/dl baseline 6 . Any rapidlyprogressing disease immediately lifethreatening illness ( defined imminent death within 48 hour opinion investigator ) 7 . Any condition circumstance , opinion investigator , would compromise safety patient quality study data 8 . Planned prior participation interventional drug study within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>